Sygnis announces the launch of its TruePrime Liquid Biopsy Kit, a ready to use amplification kit for ct-DNA (circulating tumour DNA), to be used in the detection, analysis and monitoring of early tumour stages.
Liquid biopsy, the analysis of tumour-derived DNA traces in the blood of a patient, has the potential to revolutionise diagnostic medicine, particularly in oncology.
Current techniques for cell-free DNA (cf-DNA) analysis are limited due to a lack of sensitivity. These limitations are inherently linked with the low abundance of ct-DNA present in bodily fluid samples, particularly when such samples are to be analysed by next generation sequencing (NGS).
While the underlying technology for the TruePrime technology is already covered by granted patents in several jurisdictions and additional patent application to protect this very commercially attractive application has recently been submitted.
In addition to becoming a valuable tool in oncology research this technology will also have utility in the field of precise medicine and has the potential to take up a piviotal role in the diagnosis and monitoring of cancer.
The past 10 years have seen enormous progress in both the understanding of cancer disease as well as the development of targeted therapies.
Liquid biopsy is one of the fastest developing areas in this field, with a huge potential to revolutionise diagnostic medicine. Estimations for the global liquid biopsy market in 2020 range upwards from a conservative $1.3 billion.
